Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 330Breast Neoplasms 185Lung Neoplasms 177Ovarian Neoplasms 156Triple Negative Breast Neoplasms 88Fallopian Tube Neoplasms 75Squamous Cell Carcinoma of Head and Neck 74Small Cell Lung Carcinoma 67Esophageal Neoplasms 55Neoplasms 49Head and Neck Neoplasms 47Carcinoma, Ovarian Epithelial 44Uterine Cervical Neoplasms 36Esophageal Squamous Cell Carcinoma 36Endometrial Neoplasms 35Prostatic Neoplasms 33Neoplasm Metastasis 32Lymphoma, Large B-Cell, Diffuse 32Recurrence 31Adenocarcinoma of Lung 31Lymphoma 30Brain Neoplasms 29Neuroblastoma 24Central Nervous System Neoplasms 24Retinoblastoma 23Lymphoma, Non-Hodgkin 23Carcinoma, Squamous Cell 23Hodgkin Disease 20Testicular Neoplasms 19Urinary Bladder Neoplasms 16

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × Carboplatin × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡